~~<i id='526B62658A'><strike id='526B62658A'><tt id='526B62658A'><pre id='526B62658A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

leisure time

author：leisure time 2025-09-27 10:03:05 - browse：711

Introducing STAT’s Biotech Q2 Scorecard, our emoji-enabled means of tracking 12 make-or-break events expected over the next three months.

When each clinical trial or FDA decision crosses the wires, we’ll add in the appropriate rocket ship, grimace face, bulging bicep or broken heart — whatever captures the mood.

Read on for brief explanations of what we’re watching for from each company.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： General Catalyst, Summa Health deal will turn on physician buy

entertainment

hotspot

Wikipedia

knowledge

explore

SarahSilbiger/GettyImagesWASHINGTON—Doctorswillgeta1.68%payhikeinMedicarestartingMarch9underadealstr

WSS

New Ultima Genomics DNA sequencer can read genome for $100

Medical device lobby: We're tired of waiting on Medicare coverage

Change Healthcare cyberattack outage could last weeks

AstraZeneca loses challenge to Medicare drug price negotiation

Quicker fix for pulse oximeters urged during FDA public meeting

Woodcock on FDA’s accelerated approval and her next chapter

focus

leisure time

entertainment

Apple is now the first public company to be valued at $3 trillion

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medical device lobby: We're tired of waiting on Medicare coverage

Moonlake's readout produced a cash windfall. Risks remain

Cybersecurity threat forces Lurie Children's to take systems offline

Medicare details structure of new drug price negotiation program

Do digital therapeutics have a future in medicine?

DIEP, the 'gold standard' of breast reconstruction, is under threat

What we need to know about Arena Bioworks

entertainment

Cognito secures funding to test medical device for Alzheimer's

New Ultima Genomics DNA sequencer can read genome for $100

Time to name cancers by genetics, not organ of origin, expert says

House looks to weaken Medicare negotiation

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

FogPharma raises $145 million in rare Series E round

hotspot

Wikipedia

knowledge

explore